Life
Briefing: STAT+: Two more drugmakers join TrumpRx
Strategic angle: Medicare delays stall breakthrough device access, ALS carriers fear research setbacks under Trump, and more biotech news
editorial-staff
1 min read
Updated 26 days ago
The recent inclusion of two additional drugmakers in the TrumpRx initiative underscores a significant shift in pharmaceutical collaboration aimed at reducing drug costs.
However, the initiative coincides with reported delays in Medicare that are hindering access to breakthrough medical devices, raising concerns about the timely delivery of innovative treatments.
Moreover, stakeholders in the ALS community are expressing fears regarding potential setbacks in research funding and development due to the current political climate surrounding healthcare initiatives.